Paid Clinical Trials in Maumee, OH
As of July 2026, 40 paid clinical trials are recruiting in Maumee, Ohio. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Maumee offers studies at sites including Taylor Cancer Research Center for conditions such as Non-Small Cell Lung Cancer, Pancreatic Cancer, Esophageal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Maumee
Trials by drug in Maumee
Filter results
Newly added in Maumee
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
40 clinical trials
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A Study of ASP3082 in Adults With Advanced Solid Tumors
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
GEMINI-NSCLC: NSCLC Biomarker Study
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
Pan-tumor MRD Study
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Stepped Approach to Reducing Risk of Suicide in Primary Care
DESTINY-PANTUMOUR04
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Top Research Study Locations in Maumee
Researchers run research studies in Maumee, OH at 7 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Taylor Cancer Research Center | Non-Small Cell Lung Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 23 |
| Advanced Medical Research | Obesity, Type 2 Diabetes, Atrial Fibrillation (AF) | 4 |
| Clinical Trial Site | High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension | 1 |
| Maumee Pediatric Associates | Suicidal Ideation, Suicide Prevention, Suicide, Attempted | 1 |
| Normunity Investigational Site | Cervical Cancer, ESCC, Endometrial Cancer | 1 |
| Taylor Cancer Center | PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic | 1 |
| Toledo Clinic Cancer Centers-Maumee | Anatomic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29, Estrogen Receptor Positive | 1 |
Active & Upcoming Studies in Maumee (2026)
Recruiting trials in Maumee grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (29 active studies)
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · Phase 3 · Immuneering Corporation
- A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC · Phase 1, Phase 2 · TRIANA Biomedicines, Inc.
Diabetes & metabolic (4 active studies)
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus · Phase 3 · AstraZeneca
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight · Phase 3 · Novo Nordisk A/S
Cardiovascular (4 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation · Phase 2 · Regeneron Pharmaceuticals
Common conditions studied in Maumee
- Non-Small Cell Lung Cancer (6 active studies)
- Pancreatic Cancer (5 active studies)
- Esophageal Cancer (4 active studies)
- PDAC - Pancreatic Ductal Adenocarcinoma (4 active studies)
- Endometrial Cancer (3 active studies)
- NSCLC (3 active studies)
Leading research sponsors in Maumee
- AstraZeneca
- Revolution Medicines, Inc.
- Tempus AI
- Novo Nordisk A/S
- Alnylam Pharmaceuticals
Frequently asked questions
How many paid clinical trials are currently recruiting in Maumee?
There are approximately 40 recruiting clinical trials in Maumee, Ohio listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Maumee pay participants?
Most recruiting trials in Maumee compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Maumee?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Maumee?
The most common conditions under active study in Maumee include Non-Small Cell Lung Cancer (6), Pancreatic Cancer (5), Esophageal Cancer (4), PDAC - Pancreatic Ductal Adenocarcinoma (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Maumee?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Maumee on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Maumee?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Maumee?
Recruiting research sites in Maumee include Taylor Cancer Research Center, Advanced Medical Research, Clinical Trial Site, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Maumee right now?
The largest active categories in Maumee are Cancer & tumors (29), Diabetes & metabolic (4), Cardiovascular (4). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.